Stocks News Buzz: Under Armour Inc (NYSE:UA), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

On Wednesday, Shares of Under Armour Inc (NYSE:UA), added 0.83% and closed at $31.59 in the last trading session. The last trading range of the stock ranges between $30.25 and $31.83. Under Armour, Inc. together with its auxiliaries, develops, markets, and distributes branded performance apparel, footwear, and accessories for men, women, and youth mainly in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. The company offers its apparel in compression, fitted, and loose types to be worn in hot, cold, and in between the extremes. It provides various footwear products, counting football, baseball, lacrosse, softball and soccer cleats, slides, performance training, running, basketball, and outdoor footwear. The company also offers accessories, which include headwear, bags, and gloves; and digital fitness platform licenses and subscriptions, in addition to digital advertising, in addition to licenses its brands. It mainly provides its products under the UA Logo, UNDER ARMOUR, UA, ARMOUR, HEATGEAR, COLDGEAR, ALLSEASONGEAR, PROTECT THIS HOUSE, and I WILL, in addition to ARMOURBITE, ARMOURSTORM, ARMOUR FLEECE, and ARMOUR BRA trademarks.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), jumped 7.56% and closed at $28.87 in the last trading session. The last trading range of the stock ranges between $27.37 and $29.20. The company’s Market capitalization is $4.08 Billion with the total Outstanding Shares of 121.11 million. ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has accomplished the Phase III pivotal trials for the treatment of Parkinson’s disease psychosis and the Phase II trial for the treatment of schizophrenia, in addition to is in Phase II study for the treatment of Alzheimer’s disease psychosis.

Leave a Reply

Your email address will not be published. Required fields are marked *